GlaxoSmithKline PLC (NYSE:GSK) was set to announce a $2.8 billion deal to buy biotech outfit Human Genome Sciences early Monday, several financial news outlets reported, ending a three-month pursuit of the merger.
Glaxo, Britain's biggest drugmaker, was set to pay around $14 per share, two unnamed sources told Reuters, an increase from the $13 hostile offer the company had previously made. The acquisition is seen as a way for the drugmaker, which has an aging pipeline for new drugs to acquire a wider portfolio of offerings. The prize draw is considered to be Benlysta, a lupus medication.
This article is copyrighted by International Business Times, the business news leader